Skip to content

Effect of remazolam on root canal recovery in children under combined anesthesia

Effect of remimazolam on emergence agitation for root canal therapy in children under combined anesthesia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075012
Enrollment
Unknown
Registered
2023-08-23
Start date
2023-08-31
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

emergency agitation

Interventions

G group:Anesthesia induction: assist the child to perform inhalation anesthesia (sevoflurane 8%) by behavioral induction such as "balloon blowing", intravenous injection of remazolam 0.2mg/kg, remifen
Anesthesia maintenance: inhalation of 2% sevoflurane, intravenous pump remazolam 0.5~1mg/kg, remifentanil 05~1µg/kg/min
P group:Anesthesia induction: Using behavioral induction methods such as "blowing balloons" to assist children with inhalation anesthesia (8% sevoflurane), intravenous injection of propofol 2mg/kg, an
Anesthesia maintenance: Inhalation of 2% sevoflurane, intravenous infusion of 0.5~1mg/kg remimazolam, and 0.5~1 mg/kg remifentanil µ G/kg/min

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 7 Years

Inclusion criteria

Inclusion criteria: 1) Children receiving outpatient root canal treatment under general anesthesia; 2) Age 2~7 years old, ASA grade 1 or 2, gender is not limited; 3) All patients gave informed consent and signed informed consent for surgical anesthesia.

Exclusion criteria

Exclusion criteria: 1) Congenital heart disease (patent ductus arteriosus, tetralogy of Fallot, ventricular septal defect, etc.); 2) Respiratory diseases (upper respiratory tract infection, lung infection, bronchial asthma, etc., within the last two weeks); 3) rhinitis or nasal deformity; 4) intellectual disability and suffering from other psychiatric disorders (such as mania, schizophrenia, mental disorder and cognitive dysfunction); 5) Allergic to remazolam, propofol and opioids;

Design outcomes

Primary

MeasureTime frame
emergence agitation;

Secondary

MeasureTime frame
The incidence of bradycardia;PAED score and Anno score;Anesthesia induction time;

Countries

China

Contacts

Public ContactNa Xing

The First Affiliated Hospital of Zhengzhou University

16427485@qq.com+86 139 4909 5172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026